Abstract:Abstract Background Aberrant changes in epigenetic mechanisms such as histone modifications play an important role in cancer progression. PRMT1 which triggers asymmetric dimethylation of histone H4 on arginine 3 (H4R3me2a) is upregulated in human colorectal cancer (CRC) and is essential for cell proliferation. However, how this dysregulated modification might contribute to malignant transitions of CRC remains poorly understood. Methods In this study, we integrated biochemical assays including protein interaction studies and chromatin immunoprecipitation (ChIP), cellular analysis including cell viability, proliferation, colony formation, and migration assays, clinical sample analysis, microarray experiments, and ChIP-Seq data to investigate the potential genomic recognition pattern of H4R3me2s in CRC cells and its effect on CRC progression. Results We show that PRMT1 and SMARCA4, an ATPase subunit of the SWI/SNF chromatin remodeling complex, act cooperatively to promote colorectal cancer (CRC) progression. We find that SMARCA4 is a novel effector molecule of PRMT1-mediated H4R3me2a. Mechanistically, we show that H4R3me2a directly recruited SMARCA4 to promote the proliferative, colony-formative, and migratory abilities of CRC cells by enhancing EGFR signaling. We found that EGFR and TNS4 were major direct downstream transcriptional targets of PRMT1 and SMARCA4 in colon cells, and acted in a PRMT1 methyltransferase activity-dependent manner to promote CRC cell proliferation. In vivo, knockdown or inhibition of PRMT1 profoundly attenuated the growth of CRC cells in the C57BL/6 J-Apc Min/+ CRC mice model. Importantly, elevated expression of PRMT1 or SMARCA4 in CRC patients were positively correlated with expression of EGFR and TNS4, and CRC patients had shorter overall survival. These findings reveal a critical interplay between epigenetic and transcriptional control during CRC progression, suggesting that SMARCA4 is a novel key epigenetic modulator of CRC. Our findings thus highlight PRMT1/SMARCA4 inhibition as a potential therapeutic intervention strategy for CRC. Conclusion PRMT1-mediated H4R3me2a recruits SMARCA4, which promotes colorectal cancer progression by enhancing EGFR signaling.

GMEB2 Promotes the Growth of Colorectal Cancer by Activating ADRM1 Transcription and NF-κB Signalling and Is Positively Regulated by the m 6 A Reader YTHDF1.

YY1 Promotes Colorectal Cancer Proliferation Through the Mir-526B-3p/e2f1 Axis.

Single-cell N6-methyladenosine Regulator Patterns Guide Intercellular Communication of Tumor Microenvironment That Contribute to Colorectal Cancer Progression and Immunotherapy

MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression

Gdf15 Promotes Emt And Metastasis In Colorectal Cancer

E2F1 Promote the Aggressiveness of Human Colorectal Cancer by Activating the Ribonucleotide Reductase Small Subunit M2

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2

M6a Reader PRRC2A Promotes Colorectal Cancer Progression Via CK1ε-Mediated Activation of WNT and YAP Signaling Pathways.

GPR176 Promotes Cancer Progression by Interacting with G Protein GNAS to Restrain Cell Mitophagy in Colorectal Cancer

The m6A reader IGF2BP3 Facilitates Gastric Cancer Progression Through Activating EMT via Upregulating MYC mRNA Stability

DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation

MFAP2, Upregulated by M1a Methylation, Promotes Colorectal Cancer Invasiveness Via CLK3.

A Feedback Loop Between GATA2-AS1 and GATA2 Promotes Colorectal Cancer Cell Proliferation, Invasion, Epithelial-Mesenchymal Transition and Stemness Via Recruiting DDX3X

IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism

N6-methyladenosine Methyltransferase METTL3 Promotes Colorectal Cancer Cell Proliferation Through Enhancing MYC Expression.

MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways

GSDMB interacts with IGF2BP1 to suppress colorectal cancer progression by modulating DUSP6-ERK pathway

PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling

METTL3/YTHDF2 M6a Axis Accelerates Colorectal Carcinogenesis Through Epigenetically Suppressing YPEL5.

A MYBL2 Complex for RRM2 Transactivation and the Synthetic Effect of MYBL2 Knockdown with WEE1 Inhibition Against Colorectal Cancer